Cargando…

HMGA1 Has Predictive Value in Response to Chemotherapy in Gastric Cancer

Gastric cancer is a serious health problem worldwide. Although its incidence is decreasing, the five-year survival rate remains low. Thus, it is essential to identify new biomarkers that could promote better diagnosis and treatment of patients with gastric cancer. High-mobility group AT-hook 1 (HMGA...

Descripción completa

Detalles Bibliográficos
Autores principales: Pádua, Diana, Pinto, Débora Filipa, Figueira, Paula, Pereira, Carlos Filipe, Almeida, Raquel, Mesquita, Patrícia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774981/
https://www.ncbi.nlm.nih.gov/pubmed/35049679
http://dx.doi.org/10.3390/curroncol29010005
_version_ 1784636471782670336
author Pádua, Diana
Pinto, Débora Filipa
Figueira, Paula
Pereira, Carlos Filipe
Almeida, Raquel
Mesquita, Patrícia
author_facet Pádua, Diana
Pinto, Débora Filipa
Figueira, Paula
Pereira, Carlos Filipe
Almeida, Raquel
Mesquita, Patrícia
author_sort Pádua, Diana
collection PubMed
description Gastric cancer is a serious health problem worldwide. Although its incidence is decreasing, the five-year survival rate remains low. Thus, it is essential to identify new biomarkers that could promote better diagnosis and treatment of patients with gastric cancer. High-mobility group AT-hook 1 (HMGA1) is a non-histone, chromatin-binding protein that has been found overexpressed in several tumor types. It has been correlated with invasion, metastasis, and drug resistance, leading to worse patient survival. The aim of this work was to evaluate the clinical value of HMGA1 in gastric cancer. HMGA1 expression was analyzed by immunohistochemistry in a single hospital series (n = 323) of gastric adenocarcinoma cases (stages I to IV) with clinicopathological and treatment data. In this series, HMGA1 expression showed no significant relevance as a prognostic biomarker. Nevertheless, a significantly better overall survival was observed in cases with high levels of HMGA1 when they were treated with chemotherapy, compared to the nontreated ones, implying that they can benefit more from treatment than patients with low expression of HMGA1. We thereby show for the first time that HMGA1 expression has a substantial value as a biomarker of response to chemotherapy in gastric cancer.
format Online
Article
Text
id pubmed-8774981
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87749812022-01-21 HMGA1 Has Predictive Value in Response to Chemotherapy in Gastric Cancer Pádua, Diana Pinto, Débora Filipa Figueira, Paula Pereira, Carlos Filipe Almeida, Raquel Mesquita, Patrícia Curr Oncol Article Gastric cancer is a serious health problem worldwide. Although its incidence is decreasing, the five-year survival rate remains low. Thus, it is essential to identify new biomarkers that could promote better diagnosis and treatment of patients with gastric cancer. High-mobility group AT-hook 1 (HMGA1) is a non-histone, chromatin-binding protein that has been found overexpressed in several tumor types. It has been correlated with invasion, metastasis, and drug resistance, leading to worse patient survival. The aim of this work was to evaluate the clinical value of HMGA1 in gastric cancer. HMGA1 expression was analyzed by immunohistochemistry in a single hospital series (n = 323) of gastric adenocarcinoma cases (stages I to IV) with clinicopathological and treatment data. In this series, HMGA1 expression showed no significant relevance as a prognostic biomarker. Nevertheless, a significantly better overall survival was observed in cases with high levels of HMGA1 when they were treated with chemotherapy, compared to the nontreated ones, implying that they can benefit more from treatment than patients with low expression of HMGA1. We thereby show for the first time that HMGA1 expression has a substantial value as a biomarker of response to chemotherapy in gastric cancer. MDPI 2021-12-23 /pmc/articles/PMC8774981/ /pubmed/35049679 http://dx.doi.org/10.3390/curroncol29010005 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pádua, Diana
Pinto, Débora Filipa
Figueira, Paula
Pereira, Carlos Filipe
Almeida, Raquel
Mesquita, Patrícia
HMGA1 Has Predictive Value in Response to Chemotherapy in Gastric Cancer
title HMGA1 Has Predictive Value in Response to Chemotherapy in Gastric Cancer
title_full HMGA1 Has Predictive Value in Response to Chemotherapy in Gastric Cancer
title_fullStr HMGA1 Has Predictive Value in Response to Chemotherapy in Gastric Cancer
title_full_unstemmed HMGA1 Has Predictive Value in Response to Chemotherapy in Gastric Cancer
title_short HMGA1 Has Predictive Value in Response to Chemotherapy in Gastric Cancer
title_sort hmga1 has predictive value in response to chemotherapy in gastric cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774981/
https://www.ncbi.nlm.nih.gov/pubmed/35049679
http://dx.doi.org/10.3390/curroncol29010005
work_keys_str_mv AT paduadiana hmga1haspredictivevalueinresponsetochemotherapyingastriccancer
AT pintodeborafilipa hmga1haspredictivevalueinresponsetochemotherapyingastriccancer
AT figueirapaula hmga1haspredictivevalueinresponsetochemotherapyingastriccancer
AT pereiracarlosfilipe hmga1haspredictivevalueinresponsetochemotherapyingastriccancer
AT almeidaraquel hmga1haspredictivevalueinresponsetochemotherapyingastriccancer
AT mesquitapatricia hmga1haspredictivevalueinresponsetochemotherapyingastriccancer